 SAN FRANCISCO, Aug. 13, 2021 PRNewswire -- Schubert Jonckheer Kolbe LLP is investigating potential derivative claims on behalf of shareholders of Odonate Therapeutics, Inc. NASDAQ: ODT relating to possible false statements to investors regarding its only product, tesetaxel, a drug the company was formerly developing for the treatment of breast cancer. A securities class action in the U.S. District Court for the Southern District of California recently survived a motion to dismiss allegations that between December 7, 2017 and March 19, 2021, Odonate and its CEO, CFO, and COO made false and misleading statements about the safety of tesetaxel, which was then undergoing a Phase 3 clinical trial for the treatment of breast cancer. 